Medicare began a temporary pilot program on July 1, 2026 [3], providing eligible seniors access to GLP-1 obesity medications.
This initiative removes significant financial barriers for older adults who previously could not afford these high-cost weight-loss drugs. By lowering the cost of entry, the federal government aims to improve health outcomes for a population prone to obesity-related complications.
The program, referred to as the "Bridge" program, allows eligible beneficiaries to obtain the medications with a monthly copay of $50 [1]. This temporary measure is designed to run for one year [4]. According to a Medicare spokesperson, the program will cover GLP-1 drugs for up to three million beneficiaries [3].
Analysts suggest the move creates a massive commercial opportunity for pharmaceutical companies. "This is a watershed move that could unlock a vast new patient population for Novo Nordisk and Eli Lilly," Annika Constantino said [1].
However, the program has faced criticism regarding the underlying cost of the drugs. Sen. Bernie Sanders (I-VT) criticized the pricing structures of the manufacturers. "The drugmakers are treating the United States as a cash cow," Sanders said [2].
Eligible participants include Medicare beneficiaries aged 65 and older [1]. The program operates across the U.S. to address the high cost barriers that previously kept these medications out of reach for the elderly [1]. While the program provides immediate relief, its temporary status means beneficiaries may face a coverage gap once the one-year pilot concludes [4].
“The program, referred to as the "Bridge" program, allows eligible beneficiaries to obtain the medications with a monthly copay of $50.”
The introduction of the Bridge program signals a shift in federal health policy toward recognizing obesity as a treatable condition for seniors. While it provides immediate access to millions, the one-year duration suggests the government is testing the fiscal impact of GLP-1 coverage before committing to a permanent expansion. The tension between patient access and pharmaceutical pricing remains a central conflict in the rollout.
